- Home
- PSF vs BDSX Comparison
PSF vs BDSX Comparison
Compare PSF & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSF
- BDSX
- Stock Information
- Founded
- PSF 2010
- BDSX 2005
- Country
- PSF United States
- BDSX United States
- Employees
- PSF N/A
- BDSX N/A
- Industry
- PSF Investment Managers
- BDSX Precision Instruments
- Sector
- PSF Finance
- BDSX Health Care
- Exchange
- PSF Nasdaq
- BDSX Nasdaq
- Market Cap
- PSF 256.1M
- BDSX 245.3M
- IPO Year
- PSF N/A
- BDSX 2020
- Fundamental
- Price
- PSF $21.30
- BDSX $1.68
- Analyst Decision
- PSF
- BDSX Strong Buy
- Analyst Count
- PSF 0
- BDSX 4
- Target Price
- PSF N/A
- BDSX $3.08
- AVG Volume (30 Days)
- PSF 25.0K
- BDSX 238.6K
- Earning Date
- PSF 01-01-0001
- BDSX 11-05-2024
- Dividend Yield
- PSF 7.69%
- BDSX N/A
- EPS Growth
- PSF N/A
- BDSX N/A
- EPS
- PSF N/A
- BDSX N/A
- Revenue
- PSF N/A
- BDSX $60,902,000.00
- Revenue This Year
- PSF N/A
- BDSX $48.06
- Revenue Next Year
- PSF N/A
- BDSX $29.97
- P/E Ratio
- PSF N/A
- BDSX N/A
- Revenue Growth
- PSF N/A
- BDSX 46.25
- 52 Week Low
- PSF $16.00
- BDSX $1.15
- 52 Week High
- PSF $20.19
- BDSX $2.21
- Technical
- Relative Strength Index (RSI)
- PSF 65.38
- BDSX 43.43
- Support Level
- PSF $21.11
- BDSX $1.65
- Resistance Level
- PSF $21.60
- BDSX $1.80
- Average True Range (ATR)
- PSF 0.17
- BDSX 0.07
- MACD
- PSF -0.02
- BDSX -0.01
- Stochastic Oscillator
- PSF 58.33
- BDSX 34.62
About PSF Cohen & Steers Select Preferred and Income Fund Inc.
Cohen & Steers Select Preferred and Income Fund Inc is a diversified, closed-end investment company. The Fund's primary investment objective is high current income with capital appreciation as its secondary objective. The Fund invests at least of its Managed Assets in preferred and other income securities issued by U.S. and non-U.S. companies.
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.